Ignite Creation Date:
2024-05-06 @ 3:05 AM
Last Modification Date:
2024-10-26 @ 11:28 AM
Study NCT ID:
NCT02200653
Status:
COMPLETED
Last Update Posted:
2014-07-25
First Post:
2014-07-24
Brief Title:
A Trial Comparing MICARDIS Telmisartan and COZAAR LORZAAR Losartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring ABPM
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Prospective Randomised Double-Blind Double-Dummy Titration-to-Response Trial Comparing MICARDIS Telmisartan 40 or 80 mg po Once Daily and COZAAR LORZAAR Losartan 50 or 100 mg po Once Daily in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring TOPAS STUDY Telmisartan and LOsartan ComParative ABPM Study
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TOPAS
Brief Summary:
The primary aim of the trial is to compare the influence of MICARDIS telmisartan and COZAAR LORZAAR losartan in lowering ambulatory diastolic blood pressure DBP during the last 6 hours of the 24-hour dosing interval as measured by ABPM Secondary objectives include evaluations of 1 change from baseline in mean systolic blood pressure SBP during the last 6 hours of the 24-hour dosing interval as measured by ABPM 2 changes from baseline in SBP and DBP during other periods during the 24-hour ABPM profile 3 changes from baseline in mean seated trough SBP and DBP as measured by manual cuff sphygmomanometer and 4 responder rates based on both ABPM and trough cuff blood pressure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None